Reduce your recruitment timelines

Using our efficient recruitment techniques, adaptive study designs and integrated protocols we can run hybrid studies reducing our sponsors’ drug development time.

Examples of our accelerated recruitment

Accurate costs projection. We conducted a FIH study of Lumasiran in March 2016. Our team helped to accelerate drug development using adaptive study design and provide accurate cost projections through efficient recruitment. Alnylam received marketing authorisation in April 2020.

In a study for Symptomatic Transthyretin Amyloid Cardiomyopathy, Richmond Pharmacology enrolled 11% of patients in a multi-centre study involving 104 global centres.

Reliability and operational scalability. Our in-house recruitment team enrolled 92 hypertensive patients for a global study on behalf of Alnylam, fulfilling 58% of the total cohort. Our patient networks enabled us to rapidly upscale recruitment and reduce the study timelines.

x

We enable rapid drug development

By swiftly adapting strategies to suit the unique demands of individual trials, we ensure resources are invested in the most appropriate recruitment tactics. Frequently recruiting more than our allotted cohort size in multi-centre studies, we enable our sponsors to complete enrolment early.

We are renowned for our recruitment capabilities.

Our dedicated in-house recruitment team delivers a personal service ensuring volunteers are engaged from the first contact to the last appointment.

Get in touch today

Why choose Richmond Pharmacology for Patient Recruitment in Early Phase Studies

TAP OR CLICK A BLOCK BELOW TO LEARN MORE

Strategic and efficient

You will experience a truly personal service.

Read more +

Diverse patient database

Our recruitment database is arguably the largest in Europe.

Read more +

Accurate timeline and cost predictability

We offer invaluable insight into study acceptability and suitability.

Read more +

Volunteer experience

By listening to the feedback of our volunteers, we make continuous improvements to the experience of our research participants.

Read more +

We enrol more patients safely to your study in a shorter time span using our streamlined procedures

Latest news

PATIENT WITH RARE BLEEDING DISORDER BECOMES FIRST TO TEST NEW TREATMENT

May 22, 2024
The thousands of patients who participate in Richmond’s trials are helping to advance medical science and save lives and, in the process, some make history. In a film released today, one trial participant tells her story.
Read more

Recruiting breastfeeding mothers into clinical trials through transparent and sensitive conversations

April 30, 2024
Richmond Pharmacology's study on merotocin showed low transfer to breast milk, overcoming recruitment challenges through proximity to a maternity ward.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event